Mark H. O’Hara - Concepedia

Author

Mark H. O’Hara

Also Known As

M Ohara, M O’Hara, M. O'HARA, M. O'Hara, M.H. O’Hara, Mark H O'Hara, Mark H O’Hara, Mark H. O'Hara, Mark H. O’Hara, Mark O'Hara

222

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

University of Pennsylvania The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy Hospital of the University of Pennsylvania

About

Mark H. O’Hara is an author at University of Pennsylvania specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	24	2.7K
2	Health Sciences	3	3	46
3	Engineering	2	2	291
4	Natural Sciences	1	1	45
5	Biology	1	1	45

Mark H. O’Hara

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial Gregory L. Beatty, Mark H. O’Hara, Simon F. Lacey, Gastroenterology Cancer ImmunosurveillancePancreatic CancerImmunologyAntigen ProcessingImmunotherapy	2018	487
Hepatocytes direct the formation of a pro-metastatic niche in the liver Jae W. Lee, Meredith L. Stone, Paige M. Porrett, Nature HepatologyLiver PhysiologyPro-metastatic NicheHistopathologyHepatobiliary Tumor	2019	407
An NK-like CAR T cell transition in CAR T cell dysfunction Charly R. Good, M. Ángela Aznar, Shunichiro Kuramitsu, Cell Autoimmune DiseaseT-regulatory CellImmunologyAutoimmunityCellular Immune Response	2021	376
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers Andrew R. Haas, János L. Tanyi, Mark H. O’Hara, Molecular Therapy	2019	357
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Lacey Padrón, Deena M. Maurer, Mark H. O’Hara, Nature Medicine Randomized Phase 2Pancreatic CancerGastrointestinal OncologyMedicineImmunologic Analyses	2022	316
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary, The Lancet Oncology Phase 1BPancreatic CancerMetastatic Pancreatic AdenocarcinomaMedicineImmunology	2020	286
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer Thomas B. Karasic, Mark H. O’Hara, Arturo Loaiza‐Bonilla, JAMA Oncology	2019	277
Combining Machine Learning and Nanofluidic Technology To Diagnose Pancreatic Cancer Using Exosomes Jina Ko, Neha Bhagwat, Stephanie S. Yee, ACS Nano Cancer DiagnosticsEngineeringMachine LearningExtracellular MicrovesiclesBiomedical Engineering	2017	246
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i> Kim A. Reiss, Rosemarie Mick, Mark H. O’Hara, Journal of Clinical Oncology	2021	227
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer Katelyn T. Byrne, Courtney B. Betts, Rosemarie Mick, Clinical Cancer Research	2021	170

Page 1